Tag: News Approved

Posted on

Group-based ACT for Psychological Distress of Young People

Conditions: Depression – Major Depressive Disorder; Depression Anxiety Disorder; Anxiety; Anxiety Depression

Interventions: Other: Group-based Acceptance and Commitment Therapy; Other: TAU

Sponsors: Sorlandet Hospital HF; University of Oslo; Helse Sor-Ost; Karolinska Institutet; Australian Catholic University

Recruiting
Posted on

STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

CHICAGO — Patients with high risk prostate cancer that hasn’t spread typically have two standard treatment paths before them. Remove the prostate surgically, or do a combination of radiation therapy and hormone therapy. Now, with the results of a new phase 3 clinical trial, some oncologists believe a third option may soon be laid on the table: surgery with hormone therapy both before and after the operation.

The study, called the PROTEUS trial, found that combining two hormone therapies both before and after surgery was superior to just one hormone therapy before and after surgery in high risk, early stage prostate cases. 

There is a range in how prostate cancer experts are interpreting the results, however. Many told STAT that they believed it would lead to a new standard of care, with Emmanual Antonarakis, a genitourinary medical oncologist at the University of Minnesota, calling it a “watershed moment” in prostate cancer in a New England Journal of Medicine editorial.

Continue to STAT+ to read the full story…

Posted on

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-x

As presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAGE-A8 peptide presented by HLA-A*02:01—encouraging safety and a preliminary efficacy signal were observed in patients with head and neck cancers and melanoma, including those treated with both the engager and anti-PD-1.

Posted on

STAT+: A standing ovation for RevMed, and caution for Akeso

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.  

Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted standing ovations, and the hoots and cheers were not held for the end.

The plenary may have passed, but ASCO isn’t over yet— we’ll be back tomorrow with our final newsletter installment, and you can catch our virtual recap on Wednesday.

Continue to STAT+ to read the full story…

Posted on

Ultra-low doses could bring costly cancer treatments to more patients in poorer countries

CHICAGO — What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose?

A lower-cost immunotherapy approach could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to results presented Sunday at the annual meeting of the American Society of Clinical Oncology.

Read the rest…

Posted on

STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of death in patients with squamous non-small cell lung cancer by 34% compared to a standard treatment in a clinical trial conducted entirely in China by the drug’s developer, Akeso Therapeutics, according to data presented Sunday.

The result, oncologists say, exceeded their expectations, and it appears it could generate optimism for the drug, which is being developed outside China by Summit Therapeutics. But the data also are likely to fuel debate on issues like the role of China in drug development and the future of cancer treatments. The results were presented here at the annual meeting of the American Society of Clinical Oncology and are being published simultaneously in The Lancet.

Robert Duggan, Summit’s co-CEO and chairman, said that the data mean the company has “a very valuable business with a very valuable product that is in its early stages.” Akeso had no comment for this story.

Continue to STAT+ to read the full story…

Posted on

STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug

CHICAGO — Rachna Shroff, a physician and pancreatic cancer expert, was seeing patients at the University of Arizona Cancer Center in April when she heard the striking clinical results about an experimental pill called daraxonrasib. Patients taking the targeted drug lived nearly twice as long as patients offered standard chemotherapy — an outcome never seen before in the pancreatic cancer field. 

“Having treated pancreatic cancer for 16 years, I actually started crying in the clinic,” Shroff said at a media briefing. “This is such an incredibly impactful study for our patients.”

On Sunday, detailed results from the daraxonrasib clinical trial conducted by the drug’s maker, the biotech company Revolution Medicines, were presented here at the plenary session of the annual meeting of the American Society of Clinical Oncology. The study was published simultaneously in the New England Journal of Medicine. 

Continue to STAT+ to read the full story…

Posted on

STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.  

A huge thanks to everyone who attended the jam-packed STAT @ ASCO event last night. The bao buns were incredible. IYKYK.

Don’t forget to sign up for our ASCO virtual recap on Wednesday.

Continue to STAT+ to read the full story…

Posted on

STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says

CHICAGO — Rick Pazdur, the former top oncology regulator at the Food and Drug Administration, said the damage done under recent political appointees opens a chance for new leadership to fundamentally restructure the FDA, particularly as China’s drug industry grows more competitive. 

Under leaders appointed by the Trump administration, “we’ve had a lot of destruction here, and it doesn’t mean that we have to just go back and say, well, let’s rebuild it as it was,” Pazdur said Friday night at a STAT event during the annual meeting of the American Society of Clinical Oncology. “This gives us a great opportunity of — how we want to build it, what staff we want to have, how we want the administrative structure to be.”

He said the FDA has lost many valuable experts and one way to bolster the workforce is to “think creatively,” such as bringing in academics and people in the drug industry for one- or two-year terms.

Continue to STAT+ to read the full story…